Shenzhen Chipscreen Biosciences Co., Ltd.

SHSE:688321 Stock Report

Market Cap: CN¥8.6b

Shenzhen Chipscreen Biosciences Future Growth

Future criteria checks 2/6

Shenzhen Chipscreen Biosciences is forecast to grow earnings and revenue by 64.9% and 28.6% per annum respectively. EPS is expected to grow by 64.7% per annum. Return on equity is forecast to be -0.9% in 3 years.

Key information

64.9%

Earnings growth rate

64.7%

EPS growth rate

Pharmaceuticals earnings growth18.8%
Revenue growth rate28.6%
Future return on equity-0.9%
Analyst coverage

Low

Last updated30 Oct 2024

Recent future growth updates

No updates

Recent updates

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 50% Price Boost Is Out Of Tune With Revenues

Oct 08
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 50% Price Boost Is Out Of Tune With Revenues

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price In Tune With Revenues

Aug 21
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price In Tune With Revenues

We Think Shenzhen Chipscreen Biosciences (SHSE:688321) Has A Fair Chunk Of Debt

Jun 04
We Think Shenzhen Chipscreen Biosciences (SHSE:688321) Has A Fair Chunk Of Debt

Investors Appear Satisfied With Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Prospects As Shares Rocket 26%

Apr 24
Investors Appear Satisfied With Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Prospects As Shares Rocket 26%

Solid Earnings May Not Tell The Whole Story For Shenzhen Chipscreen Biosciences (SHSE:688321)

Apr 05
Solid Earnings May Not Tell The Whole Story For Shenzhen Chipscreen Biosciences (SHSE:688321)

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Shares Climb 30% But Its Business Is Yet to Catch Up

Mar 06
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Shares Climb 30% But Its Business Is Yet to Catch Up

Earnings and Revenue Growth Forecasts

SHSE:688321 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,22411N/A1431
12/31/2025938-80N/A771
12/31/2024705-160N/A481
9/30/2024656-70-18829N/A
6/30/2024584-108-217-20N/A
3/31/2024548103-293-73N/A
12/31/202352489-386-157N/A
9/30/2023543168-358-70N/A
6/30/2023556192-357-101N/A
3/31/2023532-11-403-17N/A
12/31/202253017-35743N/A
9/30/20224904-38170N/A
6/30/202246310-312130N/A
3/31/202246026-180112N/A
12/31/202143022-164125N/A
9/30/2021360-32-21574N/A
6/30/2021342-5-23154N/A
3/31/202131219-21990N/A
12/31/202026931-24394N/A
9/30/202023137-18591N/A
6/30/202020231-20136N/A
3/31/202018123-201-6N/A
12/31/201917419-158-25N/A
9/30/201918137-130-16N/A
6/30/201915731N/AN/AN/A
3/31/201914228-9140N/A
12/31/201814831-11823N/A
12/31/201711124N/A3N/A
12/31/2016855N/A60N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688321 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 688321 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 688321 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 688321's revenue (28.6% per year) is forecast to grow faster than the CN market (13.9% per year).

High Growth Revenue: 688321's revenue (28.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688321 is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y